Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Cash And Cash Equivalents At Carrying Value of $29.64 million for the year ending 2025.
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -57.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from PUMA BIOTECHNOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2010 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $29.64 million | Fiscal year 2024: $69.22 million | Fiscal year 2023: $84.59 million | Fiscal year 2022: $76.20 million | Fiscal year 2021: $63.13 million | Fiscal year 2020: $85.29 million | Fiscal year 2019: $60.04 million | Fiscal year 2018: $108.42 million | Fiscal year 2017: $81.70 million | Fiscal year 2016: $194.49 million | Fiscal year 2015: $31.57 million | Fiscal year 2014: $38.54 million | Fiscal year 2013: $43.04 million | Fiscal year 2012: $137.41 million | Fiscal year 2011: $53.38 million | Fiscal year 2010: $0.00 | Fiscal year 2010: $0.00.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: